Filed by Comera Life Sciences Holdings, Inc./OTR Acquisition Corp.
Pursuant to Rule 425 under the Securities Act of 1933
and deemed filed pursuant to Rule 14a-12 under the Securities Exchange Act of 1934
Subject Companies:
Comera Life
Sciences Holdings, Inc. (Commission File No. 333-263377)
OTR Acquisition Corp. (Commission File No.
001-39708)
Comera Life Sciences and Intas Pharmaceuticals Announce Research Collaboration
WOBURN, Mass. & AHMEDABAD, India April 19, 2022 Today, Comera Life Sciences, Inc. (Comera
or the Company) and Intas Pharmaceuticals Ltd. (Intas) announced a research collaboration to develop a new generation of bio-innovative biologic medicines to improve patient
access, safety, and convenience.
Under the terms of the partnership agreement, Comera will develop a differentiated formulation of an Intas product using
Comeras innovative proprietary SQore formulation platform. Intas will initially provide research funding with the option to acquire global rights to the formulation through an
exclusive license with responsibility for subsequent development and commercialization.
We are excited to work with Comera to enhance therapeutic
options and access for patients, said Binish Chudgar, Vice Chairman and Managing Director of Intas Pharmaceuticals. This collaboration will accelerate our quest to develop innovative, value-added medicines that can make a difference in
patients lives globally, he added.
This collaboration is the latest step in our long-term partnership strategy to leverage our SQore
platform and transition from preclinical, early-stage assets to late-stage, marketed products, said Jeff Hackman, Chief Executive Officer and Chairman of Comera. We look forward to working with Intas and developing a differentiated
formulation that will make it easier for patients to use and increase healthcare savings.
About Comera Life Sciences
Leading a compassionate new era in medicine, Comera Life Sciences is applying a deep knowledge of formulation science and technology to transform essential
biologic medicines. The goal of this approach is to provide patients with the freedom of self-injectable care, reduce institutional dependency and to put patients at the center of their treatment regimen. On January 31, 2022, Comera Life
Sciences and OTR Acquisition Corp. (Nasdaq: OTRA) (OTR), a publicly traded special purpose acquisition company (SPAC), announced a proposed business combination.
To learn more about the Comera Life Sciences mission, as well as the proprietary SQore platform,
visit https://comeralifesciences.com/.
About Intas Pharmaceuticals
Intas Pharmaceuticals Ltd. is a leading vertically integrated pharmaceutical company based in Ahmedabad, India, having end-to-end capabilities of formulation development, manufacturing and marketing along with backward integration of APIs. The organisation has more than 18,000 employees and 14 manufacturing sites worldwide
and sells products in more than 85 countries. The Intas Groups revenue amounted to USD 2.2 bn in FY 2020-21 and the compounded annual growth rate of revenue has been 19% in the past 5 years.
For more information, please visit www.intaspharma.com